- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02709616
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC) (PERCELLVAC)
May 23, 2022 updated by: Jian Zhang, Guangdong 999 Brain Hospital
Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)
Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy.
This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly diagnosed glioblastoma and then immunizing the patients with personalized DC-based cellular vaccine.
Immune responses to tumor antigens will be monitored.
Safety and efficacy will be observed in the study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open label, single-arm, single-institution, Phase I study designed to investigate the safety and efficacy of personalized cellular tumor vaccine for patients with newly diagnosed glioblastoma (GBM).
Newly diagnosed GBM patients will undergo tumor resection.
The tumors will be analyzed for the expression of a panel of glioma-associated antigens and immune-related genes.
Post surgical treatment will be 6 weeks standard chemotherapy with temozolomide and concurrent radiotherapy and continue cycles of temozolomide within a 28-day window.
Patients will undergo leukapheresis either after surgery or after concurrent radio/chemotherapy.
Based on individual tumor antigen expression, in vitro transcribed mRNA will be generated and used to pulse in vitro generated DCs.
The patients will be immunized i.d. and i.v.
biweekly with DC cellular vaccines.
Safety and efficacy will be monitored.
The primary objective is to assess the safety of the personalized cellular vaccines.
The secondary objective is to assess the specific T cell response to immunized vaccines.
In addition, the antitumor efficacy of the vaccines will be measured using iRANO criteria, progression-free survival and overall survival.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Guangdong 999 Brain Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed glioblastoma grade IV
- Patients at the age of 18-65.
- Patients must have undergone maximal surgical resection of the tumor.
- Patients with Karnofsky scores > or =70
- Patients with normal range of hematologic and metabolic test results.
- Patients must have no corticosteroids treatment at least one week before vaccination.
- Patients capable of understanding the study and signed informed consent.
Exclusion Criteria:
- Breast feeding females.
- Pregnant women.
- Infectious diseases HIV, HBV, HCV
- Documented immunodeficiency
- Documented autoimmune disease
- Any serious or uncontrolled medical or psychiatric conditions, for example, severe pulmonary, cardiac or other systemic disease.
- Patient inability to participate as determined by PI discretion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Personalized cellular vaccine
DC based cellular vaccine
|
Biological: DC-based cellular vaccine.
Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment.
They will receive biweekly cellular vaccines.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events and severe adverse events [safety and Tolerability]
Time Frame: 3 years since the beginning of the first vaccine
|
Incidence of adverse events and severe adverse events to measure safety and tolerability of mRNA-TAA pulsed autologous DC cellular vaccine
|
3 years since the beginning of the first vaccine
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor antigen specific T cell response
Time Frame: 4 weeks after the last vaccine
|
The frequency of peripheral CD8+ and CD4+ T cell response to the vaccine.
|
4 weeks after the last vaccine
|
Progression-free survival
Time Frame: 12 months since the beginning of the first vaccine.
|
Progression-free survival will be monitored for 1year.
|
12 months since the beginning of the first vaccine.
|
Overall survival
Time Frame: 3 years since the beginning of the first vaccine
|
Overall survival will be monitored for 3 years.
|
3 years since the beginning of the first vaccine
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jian Zhang, M.D., Guangdong 999 Brain Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2016
Primary Completion (Actual)
October 31, 2017
Study Completion (Actual)
June 30, 2019
Study Registration Dates
First Submitted
March 7, 2016
First Submitted That Met QC Criteria
March 10, 2016
First Posted (Estimate)
March 16, 2016
Study Record Updates
Last Update Posted (Actual)
May 27, 2022
Last Update Submitted That Met QC Criteria
May 23, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ag-mRNA-DC-999brain
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Personalized cellular vaccine
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...CompletedBrain Cancer | Neoplasm MetastasesChina
-
Guangdong 999 Brain HospitalJinan University Guangzhou; Beijing Tricision Biotherapeutics Inc; Trinomab Biotech...Completed
-
Cell GenesysCompletedMultiple MyelomaUnited States
-
Xuanwu Hospital, BeijingBeijing Neoantigen Biotechnology CompanyRecruitingMalignant Glioma | Recurrent GliomaChina
-
Cell GenesysCompleted
-
Cell GenesysCompleted
-
Anda Biopharmaceutical Development (Shenzhen) Co...Recruiting
-
Changhai HospitalStemirna TherapeuticsUnknownPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Colorectal Adenocarcinoma | Advanced Esophageal Squamous CarcinomaChina